You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Palbociclib, residual disease, Neoadjuvant treatment, Ki67

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Breast Cancer Trial in Spain (Palbociclib, Letrozole)

Recruiting
  • Breast Cancer
  • Barcelona, Spain
  • +7 more
Sep 3, 2021

Breast Cancer, Cancer of the Breast Trial in Saint Louis (VENTANA MIB-1 Ki67 assay, Oncotype DX® Recurrence Score, PAM50-based

Not yet recruiting
  • Breast Cancer
  • Cancer of the Breast
  • VENTANA MIB-1 Ki67 assay
  • +4 more
  • Saint Louis, Missouri
    Washington University School of Medicine
Apr 18, 2023

Breast Cancer Trial in Lisboa (Aerobic Training Group, Resistance Training Group, Control group)

Not yet recruiting
  • Breast Cancer
  • Aerobic Training Group
  • +2 more
  • Lisboa, Portugal
    Fundação Champalimaud
Jul 25, 2022

Triple Negative Breast Cancer Trial in United States (Sacituzumab govitecan-hziy (SG), Pembrolizumab, Capecitabine)

Recruiting
  • Triple Negative Breast Cancer
  • Sacituzumab govitecan-hziy (SG)
  • +2 more
  • Glendale, Arizona
  • +7 more
Jan 26, 2023

Contrast-Enhanced Mammography Scans in People With Breast Cancer

Recruiting
  • Breast Cancer
  • Contrast-Enhanced Mammography
  • Breast MRI
  • Basking Ridge, New Jersey
  • +6 more
Aug 4, 2023

Breast Cancer, Triple Negative Breast Tumors Trial in France (Nivolumab, Ipilimumab, Capecitabine)

Active, not recruiting
  • Breast Cancer
  • Triple Negative Breast Neoplasms
  • Angers, France
  • +16 more
Jul 21, 2022

Breast Cancer Trial in United States (Breast Magnetic Resonance Imaging (MRI), Contrast Enhanced Mammography (CEDM))

Active, not recruiting
  • Breast Cancer
  • Breast Magnetic Resonance Imaging (MRI)
  • Contrast Enhanced Mammography (CEDM)
  • Basking Ridge, New Jersey
  • +4 more
Mar 16, 2022

Breast Tumors Trial in Italy (Trastuzumab, Pertuzumab, Palbociclib)

Completed
  • Breast Neoplasms
  • Bologna, BO, Italy
  • +6 more
Jul 14, 2020

Residual Disease in Breast Cancer Remission After Primary

Recruiting
  • Breast Cancer
  • minimally invasive preoperative image-guided vacuum-assisted biopsy
  • Milan, Italy
    Fondazione IRCCS Istituto Nazionale dei Tumori
Jul 10, 2023

Breast Cancer Female, Hormone Receptor Positive Malignant Tumor of Breast Trial in Worldwide (Palbociclib, Endocrine therapy)

Active, not recruiting
  • Breast Cancer Female
  • Hormone Receptor Positive Malignant Neoplasm of Breast
  • Clayton, Australia
  • +24 more
Jan 5, 2022

Early-Stage Breast Carcinoma, Estrogen Receptor Positive Tumor Trial in Stockholm (Paclitaxel, Tamoxifen + Palbociclib,

Active, not recruiting
  • Early-Stage Breast Carcinoma
  • Estrogen Receptor Positive Tumor
  • Stockholm, Sweden
  • +2 more
Jul 30, 2021

HER2-Positive Primary Breast Cancer Participants With Residual Invasive Disease Following Neoadjuvant Therapy Trial (SHR-A1811,

Not yet recruiting
  • HER2-Positive Primary Breast Cancer Participants With Residual Invasive Disease Following Neoadjuvant Therapy
  • (no location specified)
Nov 7, 2023

Breast Cancer, Estrogen Receptor Positive Tumor, HER2-positive Breast Cancer Trial in Worldwide (Paclitaxel, Trastuzumab,

Active, not recruiting
  • Breast Cancer
  • +2 more
  • Brasschaat, Belgium
  • +53 more
Nov 29, 2022

Cervix Cancer, HPV Testing, Postmenopausal Women Trial in Randers (cytology, p16/ki67 dual stain cytology (DS), extended

Recruiting
  • Cervix Cancer
  • +2 more
  • cytology, p16/ki67 dual stain cytology (DS), extended genotyping, DNA methylation, viral load,
  • Randers, Central Denmark Region, Denmark
    Department of Pathology
Feb 3, 2023

Primary Breast Cancer Trial in Beijing (Vinorelbine)

Recruiting
  • Primary Breast Cancer
  • Beijing, Beijing, China
    Peking University Cancer Hospital
Oct 26, 2020

Breast Cancer Trial in United States (Letrozole, Tamoxifen, Palbociclib)

Active, not recruiting
  • Breast Cancer
  • Stamford, Connecticut
  • +10 more
Jul 15, 2022

Estrogen Receptor Positive, HER2/Neu Negative, Invasive Breast Carcinoma Trial in Los Angeles (procedure, drug, other)

Terminated
  • Estrogen Receptor Positive
  • +16 more
  • Biopsy of Breast
  • +5 more
  • Los Angeles, California
    UCLA / Jonsson Comprehensive Cancer Center
Sep 22, 2022

Breast Cancer Trial in Shenyang (palbociclib combined with letrozole, epirubicin combined with cyclophosphamide and sequential

Not yet recruiting
  • Breast Cancer
  • palbociclib combined with letrozole
  • epirubicin combined with cyclophosphamide and sequential docetaxel
  • Shenyang, Liaoning, China
    Shengjing Hospital of China Medical University
Jul 18, 2021

Breast Cancer Female Trial in Belgium (Palbociclib)

Completed
  • Breast Cancer Female
  • Anderlecht, Belgium
  • +4 more
Jun 23, 2022

Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage IA Breast Cancer AJCC v8, Anatomic Stage IB Breast Cancer AJCC v8 Trial

Active, not recruiting
  • Anatomic Stage I Breast Cancer AJCC v8
  • +20 more
  • Houston, Texas
    M D Anderson Cancer Center
Dec 12, 2022

Minimally Residual of Esophageal Cancer 001

Recruiting
  • Esophageal Carcinoma
  • Minimal Residual Disease
    • Shijiazhuang, Hebei, China
      Fourth Hospital of Hebei Medical University
    Jul 17, 2023

    Triple Negative Breast Tumors Trial (Pembrolizumab injection, Capecitabine tablets, Local radiotherapy)

    Not yet recruiting
    • Triple Negative Breast Neoplasms
    • Pembrolizumab injection
    • +2 more
    • (no location specified)
    Jul 25, 2023

    Early Breast Cancer Trial in Worldwide (Giredestrant, Anastrozole, Palbociclib)

    Completed
    • Early Breast Cancer
    • Beverly Hills, California
    • +73 more
    Jan 5, 2022

    Estrogen Receptor-positive Breast Cancer, HER2-positive Breast Cancer Trial in Shanghai (Palbociclib, trastuzumab, pyrotinib)

    Recruiting
    • Estrogen Receptor-positive Breast Cancer
    • HER2-positive Breast Cancer
    • Shanghai, Shanghai, China
      Fudan University Shanghai Cancer Hospital
    Sep 29, 2021

    Breast Cancer Trial in Gaia (Combined Aerobic and Resistance Exercise)

    Not yet recruiting
    • Breast Cancer
    • Combined Aerobic and Resistance Exercise
    • Gaia, Porto, Portugal
      Centro Hospitalar Vila Nova Gaia e Espinho
    Jul 27, 2023